CP and chronic myelogenous leukemia, BCR-ABL1 positive: In PACE, 56% and 58% of patients with T315I-mutated CML-CP receiving ponatinib 45 mg QD achieved MMR by 12 and 57 months, respectively; 60% of patients who achieved a response by 57 months were estimated to maintain MMR at 5 years [13, 35].